Transition between epithelial and mesenchymal states is a feature of both normal development and tumor progression. We report that expression of chloride channel accessory protein hCLCA2 is a characteristic of epithelial differentiation in the immortalized MCF10A and HMLE models, while induction of epithelial-to-mesenchymal transition by cell dilution, TGFb or mesenchymal transcription factors sharply reduces hCLCA2 levels. Attenuation of hCLCA2 expression by lentiviral small hairpin RNA caused cell overgrowth and focus formation, enhanced migration and invasion, and increased mammosphere formation in methylcellulose. These changes were accompanied by downregulation of E-cadherin and upregulation of mesenchymal markers such as vimentin and fibronectin. Moreover, hCLCA2 expression is greatly downregulated in breast cancer cells with a mesenchymal or claudin-low profile. These observations suggest that loss of hCLCA2 may promote metastasis. We find that higher-than-median expression of hCLCA2 is associated with a one-third lower rate of metastasis over an 18-year period among breast cancer patients compared with lowerthan-median (n ¼ 344, unfiltered for subtype). Thus, hCLCA2 is required for epithelial differentiation, and its loss during tumor progression contributes to metastasis. Overexpression of hCLCA2 has been reported to inhibit cell proliferation and is accompanied by increases in chloride current at the plasma membrane and reduced intracellular pH (pHi). We found that knockdown cells have sharply reduced chloride current and higher pHi, both characteristics of tumor cells. These results suggest a mechanism for the effects on differentiation. Loss of hCLCA2 may allow escape from pHi homeostatic mechanisms, permitting the higher intracellular and lower extracellular pH that are characteristic of aggressive tumor cells.
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Introduction
Recent studies have revealed that epithelial tissues are formed from stem cells that have mesenchymal properties (Elenbaas et al., 2001; Liao et al., 2007; Mani et al., 2008) . Reactivation of certain mesenchymal transcription factors can reverse epithelial differentiation both in vitro and in vivo, and confer invasiveness, growth factor-independence and resistance to anoikis and various toxins (Cano et al., 2000; Thiery, 2002; Mani et al., 2008) . Tumor cells frequently exploit this reversibility to escape the confines of the primary tissue.
The structures and pathways that confer functionality on differentiated tissues may have an essential roles in maintaining the differentiated state and suppressing neoplasia. For example, loss of E-and R-cadherins is associated with breast cancer progression, and knockdown of these adherens junction proteins causes epithelial-to-mesenchymal transition, EMT, in immortalized cells and metastatic behavior in transformed cells (Onder et al., 2008; Agiostratidou et al., 2009) . These events are mediated by a network of transcription factors such as Snail, Twist, Slug, Goosecoid and b-catenin-TCF that regulate, or are regulated by, these structural proteins (Polyak and Weinberg, 2009) .
The chloride channel accessory protein hCLCA2 is frequently downregulated in breast tumors and tumor cell lines (Gruber and Pauli, 1999; Li et al., 2004) . We recently demonstrated that this gene is induced by p53 in response to a variety of stresses, including DNA damage (Walia et al., 2009) . In that study, we showed that ectopic expression of hCLCA2 arrested proliferation of normal cells and induced apoptosis in cancer cell lines, whereas knockdown of hCLCA2 produced faster growth and increased resistance to doxorubicin. Apoptosis in breast cancer cells was preceded by an increase in chloride current and a reduction in intracellular pH (pHi).
Several studies indicate the importance of chloride and potassium ion current regulation in EMT and invasiveness. The potassium-chloride cotransporter KCC-3 is upregulated in invasive cervical carcinoma (Hsu et al., 2007) . Cells overexpressing KCC-3 downregulate Ecadherin and undergo EMT-like changes, while a channel inhibitor reverses these changes. Similarly, in glioma, chloride and potassium channels localize to invadopodia and regulate their function (Sontheimer, 2008) .
In this study, we sought to determine the relationship between hCLCA2 expression and epithelial differentiation. We found that not only is it a marker of differentiated cells and required for full expression of the epithelial phenotype, it is also repressed by mesenchymal transcription factors. In addition, its loss correlates with increased risk of metastasis. These results suggest that loss of hCLCA2 expression is another advantage conferred upon tumor cells by transition to a mesenchymal phenotype.
Results

hCLCA2 is a marker of epithelial differentiation in breast
Previous studies showed that hCLCA2 is expressed in normal mammary epithelium but is frequently lost in breast cancer (Gruber and Pauli, 1999; Li et al., 2004) . To confirm these conclusions, we searched publicly available data from genomic transcriptional profiling studies of breast tissue and cell lines (GEO, Oncomine and NextBio). From a profile of genes differentially expressed between myoepithelial and luminal cell layers of the breast, we found that hCLCA2 mRNA is approximately eightfold more abundant in the myoepithelial layer (Grigoriadis et al., 2006) . Data from cell culture systems that model mammary development also indicate that hCLCA2 is upregulated during differentiation. For example, primary human mammary epithelial cells (HMEC) allowed to form acini in Matrigel have fivefold higher levels of hCLCA2 than cells cultured in monolayer (Dontu et al., 2003, Supplementary Table 7) . Similarly, MCF10A cultured on permeable membranes that support normal apicobasal polarization and other aspects of differentiation have an eightfold higher level of hCLCA2 than monolayers (Marshall et al., 2009) . A gene coexpression analysis using the Oncomine Clusters software revealed that hCLCA2 expression covaries with epithelial markers, such as claudins 1 and 8, E-cadherin, tetraspannins 1 and 7, and gap junctional proteins.
We further analyzed the hCLCA2 gene-expression pattern using a comprehensive transcriptional profile of breast cancer cell lines (Charafe-Jauffret et al., 2006) . Results indicated that hCLCA2 is highly expressed in immortalized cell lines such as 184B5, MCF10A and HME-1 but generally downregulated in breast cancer cell lines ( Figure 1a ). We noted that downregulation was most dramatic in cell lines classed as mesenchymal, such as Hs578T, MDA-MB-157, SKBR-7 and MDA-MB-231, typically by more than 100-fold. We confirmed these results by reverse transcription-quantitative polymerase chain reaction (RT-qPCR) ( Figure 1b ) and immunoblot (Supplementary Figure 1) . These mesenchymal cell lines share an expression profile with a newly identified breast cancer subtype termed claudin-low. This subtype is associated with stem-cell and mesenchymal properties, triple-negative phenotype and resistance to chemotherapy (Prat et al., 2010) . Two in vitro models of HMEC transformation also display loss of hCLCA2 with acquisition of malignant properties. The HMLE cell line was immortalized from primary cells by transduction with human telomerase reverse transcriptase (hTERT) and the SV40 early region encoding large T (LT) and small T (ST) antigens (Elenbaas et al., 2001) . HMLE is non-tumorigenic and displays high levels of hCLCA2 (Figure 1c) . However, transduction of activated H-RasV12 into HMLE (HMLER) leads to an approximately 20-fold reduction in hCLCA2 expression, accompanied by enhanced mammosphere formation and tumorigenicity ( Figure 1c ; Elenbaas et al., 2001; Mani et al., 2008) .
A second in vitro progression model, the Rao series, was generated by transducing hTERT into mammary epithelial cells isolated from mammoplasties to create Rao-1 (Rao et al., 2003) . The activated H-RAS61L allele was then transduced to create Rao-2, which remains anchorage-dependent, non-tumorigenic and epithelioid. Rao-3 is an anchorage-independent derivative that arose spontaneously from Rao-2 and forms spindle cell tumors in mouse . Transcriptional profiling shows Rao-3 to be of the claudin-low subtype (C Perou, personal communication; Prat et al., 2010) . Similar to the autochthonous claudin-low cell lines, Rao-3 shows precipitous downregulation of hCLCA2, whereas Rao-2 shows upregulation relative to Rao-1 (Figure 1c ; see Discussion). Together, these data imply that hCLCA2 expression is an epithelial characteristic that is lost when cells acquire a more mesenchymal phenotype.
hCLCA2 expression in epithelial cells is conditional High expression in immortalized cells presented a conundrum because ectopically expressed hCLCA2 is growth inhibitory, causing G1 arrest in immortalized cells and apoptosis in tumor cells (Walia et al., 2009) . We considered that the cell lines tested in Figure 1 were confluent, G1-arrested monolayers at the time of RNA extraction. MCF10A cells undergo cell cycle arrest and accumulate in G0/G1 phase upon reaching confluency (Enerback et al., 2002) . Therefore, we hypothesized that hCLCA2 expression in immortal cells is conditional, induced only in contact-inhibited, non-dividing cells.
To test this concept, cells were seeded at various densities and allowed to recover for 24 h before analysis. We found that rapidly growing cells seeded at 10% density had 50-fold lower expression of hCLCA2 mRNA than cells seeded at 90% confluency, and this difference increased to 150-fold if cells were confluent for 6 days ( Figures 2a and b) . At the protein level, the difference was 17-fold ( Figure 2c ).
hCLCA2 is downregulated in EMT
We noted that sparsely seeded cells acquired a fibroblast-like morphology, whereas confluent cells formed a cobblestone pattern (Figure 2a ). It was recently reported that mammary epithelial cells such as MCF10A undergo EMT upon dilution to low cell density, switching from E-cadherin to N-cadherin, vimentin and other mesenchymal markers (Sarrio et al., 2008) . This suggested that repression of hCLCA2 in low-density cells might be due to EMT. We investigated further using HMLE, which are known to form cobblestone-like islands that exhibit an epithelial phenotype surrounded by cells that are mesenchymal in expression profile and behavior Figure 3a ; Mani et al., 2008; Walia and Elble, 2010) . We recently showed that the islands are very resistant to trypsinization while mesenchymal cells detach readily, allowing the two sub-populations to be separated by differential adhesion to substrate (Walia and Elble, 2010) .
We found that in cells fractionated by this method, hCLCA2 expression correlated directly with epithelial marker E-cadherin and inversely with mesenchymal markers (Figure 3b ). Thus, cells detached by 5 min trypsinization (normalized as 1) had B15-fold lower levels of hCLCA2 and 10-fold lower levels of E-cadherin mRNA compared with cells requiring 20 min trypsinization ( Figure 3b ). On the other hand, the 5 min fraction showed elevated expression of mesenchymal markers fibronectin by B50-fold, N-cadherin by B33.3-fold, vimentin by B33.3-fold, Twist by B20-fold and Sip-1 by B12.5-fold (Figure 3b ). Together, these results indicate that hCLCA2, similar to E-cadherin, is a marker of epithelial differentiation that is lost when cells transition to a mesenchymal phenotype.
EMT-inducing transcription factors and TGF-b repress expression of hCLCA2
EMT is known to be regulated by transcription factors such as Snail, Twist and Goosecoid that repress epithelial genes such as E-cadherin and activate those for mesenchymal proteins. Ectopic expression of these transcription factors causes EMT in multiple cell types . Because of the correspondence between expression of hCLCA2 and that of E-cadherin, we tested whether Snail could repress hCLCA2. Ectopic expression of Snail in MCF10CA1d cells repressed E-cadherin by 2.5-fold and hCLCA2 by 10-fold ( Figure  4a) . Similarly, transduction of HMLE with Snail, Twist or Goosecoid repressed hCLCA2 by B4.9-, 5.3-or 8.0-fold, respectively (Figure 4b ). Moreover, induction of EMT with TGFb resulted in a fourfold reduction of hCLCA2 in HMLE and 13-fold reduction in MCF10A (Figures 4b and c) . EMT can also be induced in HMLE by the suppression of regulatory proteins such as Ecadherin by RNA interference (Onder et al., 2008) .
Knockdown of E-cadherin reduced hCLCA2 mRNA levels by B90% (Onder et al., 2008, Supplementary Table 1) . Thus, hCLCA2 is downregulated when EMT is induced by a variety of methods in several independently immortalized cell lines. These results suggest that loss of hCLCA2 expression in post-EMT tumor cell lines is due to the activation of mesenchymal transcription factors.
hCLCA2 knockdown imparts a migratory and invasive phenotype to differentiated epithelial cells Expression of certain epithelial proteins may be required to maintain epithelial differentiation (Tanaka et al., 2006; Onder et al., 2008) . To determine whether hCLCA2 has an active role in maintaining epithelial differentiation, we knocked down its expression using the hybrid small hairpin RNA (shRNA)-miR lentiviral systems GIPZ and doxycycline-regulated TRIPZ (Open Biosystems). We noticed frequent 'hummingbird figures' in the knockdown cells, suggesting a migratory phenotype and loss of E-cadherin from cell-cell junctions (Supplementary Figure 2) . We therefore performed a wound assay. hCLCA2 knockdown accelerated wound closure of MCF10A cell monolayers over a 4-day time course (Figure 5a ). To test invasiveness, we seeded cells on Matrigel-coated membranes in Boyden chemotaxis chambers. hCLCA2 knockdown cells were about 4.5-fold more invasive than control cells (Figure 5b ). Transcriptional profiling of several markers of EMT revealed a steep reduction in E-cadherin but surprisingly modest effects on mesenchymal markers (Figure 5c ). We obtained similar results using two different shRNA inserts and two different vectors (data not shown). In contrast, immunoblots showed induction of both fibronectin and vimentin, suggesting post-transcriptional regulation of these proteins in these cells (Figure 5d ). On the other hand, E-cadherin was repressed in accordance with the mRNA profile.
To confirm these results in a cell line immortalized by different methods, we knocked down hCLCA2 in HMLE using the TRIPZ lentivirus. Addition of doxycycline greatly accelerated wound closure in knockdown cells but not in controls expressing ineffective shRNA or in parental HMLE (Figures 6a and b) . Knockdown cells were also more invasive through Matrigel in a Boyden chamber assay (Supplementary Figure 3) . Control cells plated at low density were polygonal and readily formed clusters, whereas knockdown cells had a spindle-shaped mesenchymal morphology and did not cluster (Supplementary Figure 4) . In addition, we observed that the knockdown cells grew to a higher density (Figure 6c and Supplementary Figure  5) , formed frequent foci and free-floating spheroids (Figure 6d and Supplementary Figure 6) , and produced more mammospheres in methylcellulose than did controls (Figure 6e ). Transcriptional profiling of these cells showed steep downregulation of E-cadherin and upregulation of mesenchymal markers except for fibronectin (Figure 6f ). Immunoblot analysis revealed pronounced downregulation of E-cadherin and upregulation of both vimentin and fibronectin, suggesting that fibronectin is regulated post-transcriptionally (Figures 6f and g ). These results demonstrate that hCLCA2 contributes to epithelial differentiation and illustrate how its loss would be advantageous to tumor cells.
Higher hCLCA2 expression correlates with lower breast cancer metastasis To determine whether hCLCA2 expression levels were predictive of metastasis, we interrogated a data bank that allowed comparison of primary tumor transcriptional profiles with the incidence of metastasis over an 18-year period in 344 breast cancer patients. We found that the incidence of metastasis in patients having lowerthan-median expression was 40.1% after 18 years, whereas in patients with higher-than-median expression, hCLCA2 loss in EMT and metastasis V Walia et al the incidence was only 26.7% (Figure 7) . Thus, higher expression of hCLCA2 reduced the rate of metastasis by 33.4% ( P ¼ 0.0043, n ¼ 344). These data support the hypothesis that hCLCA2 loss is an indicator of malignancy, but it was not possible to distinguish whether hCLCA2 loss was a better predictor of metastasis for any particular breast cancer subtypes.
Knockdown of hCLCA2 reduces chloride current and increases pHi CLCA proteins are thought to stimulate chloride current at the plasma membrane by modulating an unidentified chloride channel (Hamann et al., 2009) . To address the mechanism by which hCLCA2 influences epithelial differentiation, we measured the transmembrane chloride current in knockdown cells and controls after stimulating with calcium and ionomycin. We found that knockdown cells had dramatically lower chloride current than controls (Supplementary Figure 7) .
The activity of certain chloride channels has a role in regulation of pHi, which in turn affects many aspects of cell physiology (Kunzelmann, 2005) . Tumor cells typically have an alkaline pHi due to metabolic changes concomitant with tumor progression (Pouyssegur et al., 2006) . In previous work, we had found that ectopic expression of hCLCA2 stimulated chloride current and reduced pHi (Walia et al., 2009 ). Here we observed that knockdown cells had higher pHi than controls, 8.0 versus 7.6, respectively (Supplementary Figure 7) . These results suggest that downregulation of hCLCA2 during tumor progression allows metabolic changes advantageous to tumor cells.
Discussion
A number of structural and other proteins that characterize epithelial cells have turned out unexpectedly to be required for maintenance of the epithelial phenotype. In this study, we show that hCLCA2, a protein previously shown to be a p53-inducible growth inhibitor, is associated with terminal differentiation of hCLCA2 loss in EMT and metastasis V Walia et al mammary epithelial cells, but is downregulated when such cells transit to a mesenchymal phenotype. This downregulation is mediated by the same factors that were shown in other studies to drive EMT in immortalized epithelial cells and whose expression is upregulated in post-EMT metastatic cell lines. This suggests that the precipitous loss of hCLCA2 in metastatic breast cancer is due to activation of the mesenchymal program. By attenuating expression of hCLCA2, we show that hCLCA2 is not passive in this process but is required for full expression of the epithelial phenotype. The changes we observed with knockdown, such as enhanced migration, focus formation and changes in the transcriptional program, all suggest that loss of hCLCA2 abets tumor progression. This conclusion is reinforced by the finding that low expression corresponds to a higher risk of metastasis in breast cancer patients. We found that ectopic expression of Snail represses expression of hCLCA2 in parallel with E-cadherin. Snail is one of a network of transcription factors, also including Slug, Twist and Zeb, that orchestrate EMT by repressing expression of genes required for epithelial differentiation such as E-cadherin and other cell-cell junctional proteins. These factors bind to the sequence CANNTG, termed the E-box, three iterations of which are found in the E-cadherin promoter (Hajra et al., 2002) . They respond to distinct environmental cues, and all have been shown to regulate E-cadherin by direct binding to its promoter (Moustakas and Heldin, 2007) . We identified eight E-boxes within 800 bp of the transcriptional start of hCLCA2, including two near the established binding sites for p53 (VW and RCE, unpublished data) . Further studies will establish whether binding of Snail or sister proteins to these sites mediates transcriptional repression of hCLCA2 in EMT.
In breast cancer cell lines, hCLCA2 was generally downregulated relative to immortalized cells, but there were exceptions. For example, luminal-B MDA-MB-175 cells and basal HCC1937 cells had higher hCLCA2 expression than the other cancer cell lines. We speculate that these cell lines may have mutations in hCLCA2 or its responsive pathways that allow them to tolerate higher hCLCA2 levels, much as described for tumor suppressor p53. For example, p53 is only mutated in about 20% of all breast cancers (Pharoah et al., 1999) . In the rest, alterations in the upstream and downstream proteins of the p53 pathway disable its tumor suppressor activity (Gasco et al., 2002) . Further genetic studies of such cell lines may provide insight into pathways of growth inhibition by hCLCA2 and explain why its loss is not a stronger predictor of metastasis in breast cancer. In melanoma, by comparison, the transition between nonmetastatic and metastatic disease is accompanied by a 162-fold reduction in hCLCA2 levels (Riker et al., 2008) .
In vitro models of tumor progression have yielded many insights into the genetic changes required for tumor survival and metastasis. Ectopic expression of hTERT in primary cells was used to generate the immortal cell lines HMEC-Tert and Rao-1, and additional changes were made by viral transduction. We observed here that ectopic expression of activated H-Ras61L alone was insufficient to downregulate hCLCA2 in the Rao-1-immortalized line but upregulated it instead. In contrast, ectopic expression of HRasV12 in HMLE steeply downregulated hCLCA2. This cell line expresses SV40 LT, which binds and inactivates p53. We speculate that expression of HRas61L in Rao-1 induces Arf, which binds Mdm2 and stabilizes p53, thereby upregulating p53-inducible hCLCA2 (Lin and Lowe, 2001; Walia et al., 2009) . Presumably, this induction does not occur in HMLE transduced by H-RasV12, HMLER, because p53 is inactivated by LT in those cells. Ras has been shown to promote EMT by activating Snail, Slug and Rac (Polyak and Weinberg, 2009 ). Moderate activation of Snail could account for the downregulation of hCLCA2 in HMLER, but full EMT in HMLER requires ectopic expression of mesenchymal transcription factors . Presumably, these pathways have been activated by spontaneous mutation in Rao-3. The results presented here suggest that attenuation of hCLCA2 causes the loss of some epithelial properties, but alone is insufficient to produce a complete transition to a mesenchymal phenotype.
The varied effects of hCLCA2 knockdown support this view. Attenuation of hCLCA2 induced EMT more effectively in HMLE than in MCF10A (Figures 5  and 6 ). This may be due to the means by which HMLE was generated. These cells were immortalized by transduction of hTERT, LT, and ST. LT inactivates p53 and Rb, whereas ST inactivates protein phosphatase 2A, causing an increase in PI3K/AKT and other mitogenic activities (Sablina et al., 2010) . Recent studies Figure 7 Effect of hCLCA2 expression level on metastasis-free survival in breast cancer patients. Transcriptional profiles of primary breast tumors were analyzed for hCLCA2 expression and related to metastasis incidence over an 18-year period. Data are presented as a Kaplan-Meier plot of metastasis-free survival (proportion versus time) of 344 patients with high (upper line) or low (lower line) expression level of the gene 'CLCA2'. Chi-square P-value ¼ 0.00428. hCLCA2 loss in EMT and metastasis V Walia et al demonstrate that mutation of p53 potentiates EMT by several avenues, directing cells away from luminal and toward basal or mesenchymal character, especially if Rb is also mutated (D'Assoro et al., 2010; Jiang et al., 2010; Kogan-Sakin et al., 2011) . High activity of AKT also promotes EMT, by inactivating an inhibitor of Snail, GSK3b and by stabilizing nuclear factor-kB, a transactivator of Twist (Thiery and Sleeman, 2006) . Therefore, HMLE may be primed for EMT in a way that MCF10A is not, and the effect of hCLCA2 loss on EMT may depend on genetic background.
Triple-negative breast cancer has long been associated with poor prognosis and a basal transcription profile. However a distinct triple-negative subtype has recently been recognized with a mesenchymal transcription profile, the claudin-low subtype (Hennessy et al., 2009; Taube et al., 2010) . This subtype is enriched in cancer stem cells and associated with chemoresistance and other mesenchymal properties (Creighton et al., 2010) . The finding that claudinlow cell lines, whether autochthonous or selected in vitro, display dramatic downregulation of hCLCA2 supports the conclusion that hCLCA2 expression signifies epithelial differentiation and is downregulated with EMT.
The observation that knockdown of hCLCA2 leads to an increase in pHi may be significant to the altered phenotype. It has long been known that tumor cells have higher pHi than normal cells because of enhanced growth factor signaling, glycolytic metabolism and other factors. Ligation of growth factor receptors increases pHi by 0.2 units, partly due to activation of ERK, which in turn phosphorylates and activates NHE1 (Moolenaar et al., 1983; Hesketh et al., 1985; Malo et al., 2007 ). An alkaline cytosol may protect tumor cells from apoptosis because the optimal pH for caspases and apoptotic endonucleases is acidic (Barry and Eastman, 1992; Furlong et al., 1997) . Furthermore, translocation of Bax to the mitochondrial membrane is enhanced eightfold by acidic pHi, and anti-apoptotic Bcl-2 activity is enhanced at alkaline pHi (Antonsson et al., 1997) . Moreover, artificially increasing pHi of 3T3 cells by transduction of a H þ -ATPase confers serum-and anchorage-independence and tumorigenicity in mice (Perona and Serrano, 1988) . Thus, the enhanced ability of knockdown cells to form mammospheres may be partly attributable to their alkaline pH. Regulation of pHi by hCLCA2 may occur via its modulation of a chloride channel such as CFTR that is known to regulate pHi (Poulsen et al., 1994; Barriere et al., 2001) . Alternatively, the growth-inhibitory activity of hCLCA2 may arise from some yet undiscovered function of the molecule.
The results presented here are consistent with our prior studies of the hCLCA2 mouse ortholog mClca5. Similar to hCLCA2, mClca5 expression in normal cells was found to be dependent on cell density. Moreover, metastatic mesenchymal tumor cell lines such as 4T1 had greatly reduced expression and were very sensitive to ectopic expression of mClca5. Surviving colonies with stable expression had reacquired a cobblestone growth pattern (Beckley et al., 2004) . Conclusive evidence of the role of hCLCA2 in mammary differentiation and tumor suppression depends on the outcome of gene deletion studies now in progress.
Materials and methods
Cell lines and cell culture Breast cell lines MCF-10A, MCF-7, T47D, BT-549, MDA-MB-231, MDA-MB-435 and Hs578T were obtained from ATCC (Manassa, VA, USA) and grown in the media specified. HMLE and HMLER were a kind gift from Robert Weinberg (MIT, Boston, MA, USA) and were grown as described . Rao-1, -2 and -3 were cultured as described by Cheng . We thank Paul Wade (NIEHS, Research Triangle Park, NC, USA) for the generous gift of adenovirus-expressing Snail (Dhasarathy et al., 2007) . Knockdown of hCLCA2 was performed as described (Walia et al., 2009) . Lentiviral transductants were selected for at least 2 weeks in 1 mg/ml puromycin.
Bioinformatics
Oncomine (http://www.oncomine.org; Compendia Bioscience, Ann Arbor, MI, USA), Gene Expression Omnibus (http:// www.ncbi.nlm.nih.gov/geo; NCBI) and NextBio (http:// www.nextbio.com/b/nextbio.nb) were used to analyze hCLCA2 gene-expression patterns. To determine the effect of hCLCA2 on patient survival, the microarray expression data and the relevant annotation for the patient data used in this study were downloaded from the GEO repository. The accession numbers are GSE5327 (Minn et al., 2007) and GSE2034 (Wang et al., 2005) . A total of 344 Affymetrix CEL files (each per patient sample) were processed and normalized all at once using the RMA method implemented by 'affy' R package version 1.26.1 (Gautier et al., 2004) . If multiple probes exist for the same gene, the average values were used to represent the expression levels of that gene. The geneexpression levels for all samples were then scaled through Zscore transformation. An estimate of the survival curve for censored data was computed using the Kaplan-Meier method implemented by 'survival' R package version 2.35-8 by Therneau and Lumley (http://CRAN.R-project.org/package ¼ survival). All analyses were performed using the R version 2.11.1, a language and environment for statistical computing (R Development Core Team (http://www.r-project.org/)).
RNA analysis
Cells were grown to confluency except where noted, and RNA was extracted and analyzed as described (Beckley et al., 2004; Walia et al., 2009; Walia and Elble, 2010) . Primer sequences are available upon request.
Western blot analysis Levels of hCLCA2 were measured by immunoprecipitation and western blotting as described using antibody TVE20 (Elble et al., 2006) . For the cell density experiment, cleared lysates were prepared from 10-cm dishes containing cells at 10% (10 dishes), 90% (3 dishes) and 100% (2 dishes) confluency. Total protein concentration in lysates was measured by the BCA assay (Bio-Rad, Hercules, CA, USA) and 1 mg of total protein was used for immunoprecipitation. For whole-cell lysates, 50 mg protein was loaded per lane. Antibodies were from Cell Signaling (Danvers, MA, USA) except b-actin (W Halfter via the Developmental Studies Hybridoma Bank, University of hCLCA2 loss in EMT and metastasis V Walia et al Iowa, Iowa city, IA, USA). The size marker was Dual color (Bio-Rad). Protein expression was quantified on an Odyssey instrument (Licor).
Differential trypsinization HMLE cells were grown and differentially trypsinized as described (Walia and Elble, 2010) . Cells collected after 5, 10, 15 and 20 min were lyzed in Trizol for RNA extraction followed by RT-qPCR as described.
Migration and invasion assays
To quantify migration, a wound was made in the cell monolayer using a sterile 1 ml pipette tip. Migration of cells into the wound was observed after 6, 12, 24 and 48 h intervals. Photomicrographs of four different fields were compared and quantified. Invasion was measured by seeding 10 5 cells onto modified Boyden chamber inserts containing Matrigel-coated membranes (pore size 8 mm, BD Biosciences, Franklin Lakes, NJ, USA). After 6, 12, or 24 h, the inserts were stained and cells present on the lower side of the membrane were quantified manually by counting four different fields at Â 150 magnification.
Mammosphere assay
The mammosphere culture assay was performed as described Walia and Elble, 2010) . Single-cell suspensions were prepared in mammary epithelial growth medium containing 1% methylcellulose and fetal bovine serum as indicated. Mammospheres were photographed to determine their diameters.
Electrophysiology and pH measurements HMLE cells grown on poly-D-lysine-coated coverslips, which were used for recording chloride currents. For whole-cell patch-clamp recordings, the bath solution contained (in mM): 140 NaCl, 5 KCl, 10 HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid), 1 MgCl 2 , 1 CaCl 2 , pH adjusted to 7.35 with NaOH and the pipette solution contained (in mM): 140 CsCl, 5 KCl, 10 HEPES, 2 MgCl 2 , 10 ethylene glycol tetraacetic acid, 2 K 2 ATP, 0.5 GTP, pH adjusted to 7.35 with CsOH. Ionomycin (4 mM) was applied extracellularly. All the experiments were performed using voltage ramps and voltage steps from À100 mV to 100 mV. Currents were recorded using an Axopatch 200B integrating patch-clamp amplifier (Axon Instruments Inc., Union City, CA, USA). Data were digitized (VR-10B; InstruTech, Great Neck, NY, USA) and stored in the computer using Lab View interface (National Instruments, Austin, TX, USA). For analysis, data were filtered at 2.5 kHz (À3 dB frequency with an eight-pole low-pass Bessel filter; LPF-8; Warner Instruments, Hamden, CT, USA) and digitized at 5 kHz. Cell capacitance was measured manually using the readout in the Axopatch 200B amplifier. All the currents were subtracted from the control currents before application of ionomycin. Current and current density were plotted and the amplitudes were measured using Origin 6.1 (OriginLab Corporation, Northampton, MA, USA). Intracellular pH was measured essentially as described (Walia et al., 2009) .
